Key Highlights
- Corcept Therapeutics (NASDAQ:CORT) was up 3.04% at USD 121.38 in the October 14, 2026 morning session. The partial-session share volume was 42,842, and no same-day company announcement was identified as the reason for the move.
- Revenue for Q2 2026 advanced 32% to USD 256.1 million from USD 194.4 million a year earlier. Korlym and its authorized generic accounted for USD 208.6 million, according to the July 29, 2026 release.
- Net income increased to USD 43.0 million from USD 35.1 million, and diluted earnings per share came to USD 0.36 versus USD 0.29. Cash and investments totaled USD 544.6 million as of June 30, 2026.
- Corcept lifted its 2026 revenue outlook to USD 1.1 billion to USD 1.2 billion. The relacorilant new drug application for Cushing's syndrome was resubmitted in June 2026 and has a PDUFA target date of December 17, 2026.
Developments Providing Context
No Corcept announcement dated October 14 was found; the 3.04% advance on thin trading appears to sit against its July results and upcoming regulatory dates. The FDA approved Lifyorli (relacorilant) with nab-paclitaxel for platinum-resistant ovarian cancer in March 2026, while a European decision was expected by year-end. Of the USD 256.1 million Q2 revenue, USD 208.6 million came from Korlym and its authorized generic, leaving roughly USD 47.5 million from other sources when subtracting the two reported amounts. Only 42,842 shares traded during the partial morning session, so a small number of trades may have influenced the quote rather than a broad reassessment by investors.
Earnings, Guidance and FDA Timing
Corcept's diluted EPS was USD 0.36, while basic EPS was USD 0.40; the difference reflects securities that may dilute ordinary shareholders. PDUFA refers to the FDA's target date for completing an application review, and a resubmission following a complete response letter carries a defined review timetable. Guidance of USD 1.1 billion to USD 1.2 billion suggests that stronger sales are needed over the remainder of the year, assuming newer products contribute more. Cash and investments of USD 544.6 million give the company resources to continue clinical development without an immediate need for financing. Because Korlym faces generic competition, growth in revenue from other products is increasingly important.
Key Risks and Dates Ahead
The main issues to follow are generic pressure on Korlym, the FDA's decision on relacorilant for Cushing's syndrome, and the commercial trajectory of the ovarian cancer product. The December 17, 2026 PDUFA date and a European regulatory decision expected by year-end are key calendar points. The company had not announced the Q3 results date at publication and directed readers to its SEC filings for details on litigation and other risks. FDA review can be extended or result in another complete response letter, delaying a potential Cushing's syndrome launch; clinical setbacks in oncology studies could also affect expectations. This is informational context, not investment advice.
Investor Takeaway
Corcept rose 3.04% on October 14, 2026 without an identified company announcement that day. The backdrop includes 32% Q2 revenue growth, an increase in 2026 guidance, and the December 17, 2026 FDA target date for relacorilant in Cushing's syndrome. Generic competition and regulatory uncertainty remain material risks, and the Q3 report date was still unannounced. This is not investment advice.






Please wait processing your request...